Please join BioInvest FREE at The MoneyShow’s TradersEXPO in Las Vegas on April 24-26. In this session, John will explain the methodology he uses to sift through hundreds of biotech companies to find the best-in-class drugs like MDGL for longterm growth.
Please join BioInvest FREE at The MoneyShow live streaming event from December 7-9 where John McCamant will be presenting along with dozens of the most respected economists, money managers, and professional traders in the country.
Myovant Sciences Ltd. (MYOV) offers a new drug “pipeline in a pill”, asserts biotech expert Jay Silverman, contributing editor to Medical Technology Stock Letter.
Last January, MoneyShow.com asked the leading newsletter advisors to select their favorite stocks for 2019. Healthcare was a popular sector in that survey, with several big first-half winners. Here’s a check-up on six healthcare favorites poised for the second half gains in 2019.
Please join BioInvest FREE at The MoneyShow live streaming event on October 12 where John McCamant will be presenting along with dozens of the most respected economists, money managers, and professional traders in the country. #MYOV #MDGL #PGEN #TCRT
At the recent JPMorgan Conference, biotech BioMarin Pharmaceutical (BMRN) offered a presentation that included important and new information regarding its R&D pipeline for 2019, observes biotech specialist John McCamant, editor of Medical Technology Stock Letter.
On their recent conference call for The Medicines Company (MDCO), management highlighted the power of Inclisiran’s profile and likelihood of its potential to change the paradigm of ASCVD (atherosclerotic cardiovascular disease) treatment, notes biotech expert John McCamant, editor of The Medical Technology Stock Letter.
For investors interested in biotech, there’s a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times. John McCamant discusses Sangamo in this article.
Please join BioInvest FREE at The MoneyShow live streaming event on September 8 where John McCamant will be presenting along with dozens of the most respected economists, money managers, and professional traders in the country.
At the recent JPMorgan conference, ACADIA Pharmaceuticals (ACAD) presented a business update highlighting several catalysts anticipated in 2020, notes John McCamant, biotech sector expert and editor of Medical Technology Stock Letter.
Market volatility has risen sharply as investors react to short-term geopolitical news. In the biotech sector, however, investment experts tend to remain focused on long-term developments such as clinical drug trials. For those with a long-term horizon, here are some favorites from MoneyShow.com contributors.
In a rare move for a biotech expert who primarily takes bullish long-term positions, John McCamant has issued short sale recommendations for three stocks in the CRISPR space. The editor of The Medical Technology Stock Letter and contributor to MoneyShow.com explains his concerns about this specialized group while also reiterating a Strong Buy rating for one gene-editing play which does not rely on CRISPR technology.
